Fundz

Simnova Biotech secures $59.5M Series B led by Fortera Capital and Pudong Venture Capital to advance off-the-shelf cell therapies.

PRIVATESep 06, 2026

Amount Raised

$59.5 Million

Round Type

Series B

ShanghaiBiotechnology

Investors

Oriza HoldingsCenova VenturesYoushan CapitalPudong Venture CapitalFortera Capital

Description

Simnova Biotech has secured nearly CNY400 million (USD59.5 million) in its Series B funding round co-led by Shanghai state-owned investment funds Fortera Capital and Pudong Venture Capital, along with private equity firm Cenova Ventures. The funding will accelerate clinical research for the company's off-the-shelf cell therapies, particularly its lead CAR-NK program SNC103 and In Vivo CAR-T platform SNC116. Suzhou state-owned investment firm Oriza Holdings participated as a follow-on investor, while existing shareholder Youshan Capital increased its investment. Founded in 2019, Simnova focuses on off-the-shelf CAR-NK, In Vivo CAR-T, and multi-target CAR-T therapies for solid tumors.

Quick answer

Simnova Biotech raised $59.5 Million in a Series B round, dated September 6, 2026. Investors: Oriza Holdings, Cenova Ventures, Youshan Capital, Pudong Venture Capital and Fortera Capital. Simnova Biotech is based in Shanghai, China.

How much did Simnova Biotech raise?
Simnova Biotech raised $59.5 Million in a Series B round on September 6, 2026.
Who invested in Simnova Biotech?
Oriza Holdings, Cenova Ventures, Youshan Capital, Pudong Venture Capital and Fortera Capital are named as investors in this round.
What does Simnova Biotech do?
Simnova Biotech is a Chinese cell therapy startup founded in 2019, originally spun off from Simcere Pharmaceutical Group.
Where is Simnova Biotech based and how big is it?
Simnova Biotech is based in Shanghai, China. Fundz records about 8 employees.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Simnova Biotech that raised within 45 days of this round, from Fundz verified event records.

  • 511 Therapeutics raised $500K (Seed) on October 21, 2026.
  • Total Joint Orthopedics raised $11M (Debt Financing) on October 21, 2026.
  • Geneticure raised $1M (Series A) on October 21, 2026.
  • Lucid Diagnostics raised $15M (Series C) on October 21, 2026.
  • Arctic Therapeutics raised $22M on October 21, 2026.
  • Fodere Critical Minerals Limited raised $5M (Convertible Note) on October 20, 2026.

Who to call at Simnova Biotech, and when

A new round usually means Simnova Biotech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Simnova Biotech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Simnova Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Simnova Biotech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Simnova Biotech

Location

Shanghai, China

About

Simnova Biotech is a Chinese cell therapy startup founded in 2019, originally spun off from Simcere Pharmaceutical Group. The company focuses on developing off-the-shelf cell therapies using three technology platforms: CAR-NK, In Vivo CAR-T, and multi-target CAR-T therapies for solid tumors. Its lead program SNC103 is a CAR-NK cell therapy that has shown positive results in Phase I trials for systemic lupus erythematosus.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Simnova Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Simnova Biotech's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Simnova Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.